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Abstract
The first structural and biophysical data on the folate biosynthesis pathway enzyme and drug target, 6-hydroxymethyl-7,8-
dihydropterin pyrophosphokinase (SaHPPK), from the pathogen Staphylococcus aureus is presented. HPPK is the second
essential enzyme in the pathway catalysing the pyrophosphoryl transfer from cofactor (ATP) to the substrate (6-
hydroxymethyl-7,8-dihydropterin, HMDP). In-silico screening identified 8-mercaptoguanine which was shown to bind with
an equilibrium dissociation constant, Kd, of ,13 mM as measured by isothermal titration calorimetry (ITC) and surface
plasmon resonance (SPR). An IC50 of ,41 mM was determined by means of a luminescent kinase assay. In contrast to the
biological substrate, the inhibitor has no requirement for magnesium or the ATP cofactor for competitive binding to the
substrate site. The 1.65 A˚ resolution crystal structure of the inhibited complex showed that it binds in the pterin site and
shares many of the key intermolecular interactions of the substrate. Chemical shift and 15N heteronuclear NMR
measurements reveal that the fast motion of the pterin-binding loop (L2) is partially dampened in the SaHPPK/HMDP/a,b-
methylene adenosine 59-triphosphate (AMPCPP) ternary complex, but the ATP loop (L3) remains mobile on the ms-ms
timescale. In contrast, for the SaHPPK/8-mercaptoguanine/AMPCPP ternary complex, the loop L2 becomes rigid on the fast
timescale and the L3 loop also becomes more ordered – an observation that correlates with the large entropic penalty
associated with inhibitor binding as revealed by ITC. NMR data, including 15N-1H residual dipolar coupling measurements,
indicate that the sulfur atom in the inhibitor is important for stabilizing and restricting important motions of the L2 and L3
catalytic loops in the inhibited ternary complex. This work describes a comprehensive analysis of a new HPPK inhibitor, and
may provide a foundation for the development of novel antimicrobials targeting the folate biosynthetic pathway.
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Introduction
Staphylococcus aureus is a clinically important opportunistic
pathogen and one of the major contributors to hospital- and
community-acquired bacterial infections. Methicillin-resistant S.
aureus strains (MRSA, commonly referred to as the ‘‘superbug’’)
cause up to 19,000 deaths annually in the US alone, and an
estimated health care cost of $ 3–4 billion per annum [1]. MRSA
strains are classified by genotypic and phenotypic characteristics,
and are grouped into two major categories: those originating in
hospitals (nosocomial, haMRSA, strains USA100 and USA200)
and those in the community (caMRSA), of which the latter is
almost entirely caused by the pandemic USA300 strain [2].
Infection with USA300 causes abscesses and life threatening
systemic infections, such as bacteremia and necrotizing pneumo-
nia. In contrast to haMRSA, caMRSA infections tend to occur in
previously healthy younger patients without health care exposure
[3]. Currently, caMRSA is more susceptible to a range of
chemotherapies than the multi-drug resistant haMRSA [4].
Although resistant to tetracycline, erythromycin, clindamycin,
linezolid, and in some cases vancomycin, caMRSA is largely
susceptible to TMP-SMX (trimethoprim-sulfamethoxazole) com-
bination therapy, which synergistically blocks the biosynthesis of
folate derivatives by acting on dihydrofolatereductase (DHFR) and
dihydropteroatesynthase (DHPS), respectively [5,6]. TMP-SMX
resistance has emerged in haMRSA owing to an ‘autolytic’
thyamidine salvage pathway effective when polymerized DNA is
released from damaged tissues [6,7,8]. TMP-SMX resistance in
caMRSA is attributed to mutations in the DHFR or DHPS genes,
which in the former case results in a repositioning of the substrate
in the active site [9], compromising TMP-based therapy.
Classically, targets for antimicrobials are found to be essential
enzymes that are unique to the micro-organism (not present in the
host), and new antimicrobial drugs have been developed from
molecules identified in proof-of-concept studies [10]. The folate
biosynthetic pathway fits the criterion of being an attractive source
of potential target enzymes, and antimicrobials against key
components of this pathway are used today to treat diseases such
as malaria, pneumocystis pneumonia (PCP) and caMRSA
infections. Folates are essential for the growth of all living cells.
The reduced form of folate, tetrahydrofolate (THF), participates in
several important one-carbon transfers, critical for the biosynthesis
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of thymidine, glycine and methionine, and is vital for DNA
replication [11,12].
6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK,
EC 2.7.6.3) catalyses pyrophosphoryl transfer from ATP (cofactor)
to the substrate, 6-hydroxymethyl-7,8-dihydropterin (HMDP)
(Fig. 1). HPPK is the upstream and adjacent enzyme to DHPS in
the folate biosynthesis pathway (Fig. 2A). It is not the target of any
existing drug and therefore represents an attractive resource for the
rational design of novel antimicrobials and antifungals to act on
current TMP-SMX-resistant isolates for the treatment of caMRSA
infections. HPPK is a small (158 residues, ,18 kDa), generally
monomeric protein and has been studied using various biophysical
techniques, including x-ray crystallography and NMR spectrosco-
py. A number of x-ray and NMR structures of HPPK have been
determined in various ligand-bound states (Fig. 2B) and from a
variety of organisms: Escherichia coli, Haemophilusinfluenzae, Saccharo-
myces cerevisiae, Streptococcus pneumonia, Yersinia pestis and Francisella
tularensis [13,14,15,16,17,18]. These data have provided atomic
level information on the catalytic mechanism and protein dynamics
of the reaction trajectory during catalysis [19]. Three loop regions,
loops L1–3, play an important role in substrate recognition and are
critical for assembling the active centre [20]. While loop L3
undergoes the largest and most dramatic conformational change
during the catalytic cycle, all three loops help to seal the substrate
and cofactor binding sites for the chemical transfer of a
pyrophosphate from ATP to HMDP [21]. The substrate and
cofactor interact with two magnesium ions and associate with a total
of 26 residues in HPPK, 13 of which are conserved across all species
[22]. In vitro kinetic studies have shown a preferred order of substrate
binding. At cellular levels of magnesium, the ATP binds first,
followed by HMDP [23]; in the absence of cofactor and
magnesium, HMDP binds weakly in vitro to the apo enzyme [24].
Both active sites are highly selective for their ligands. For example,
the affinity of E. coli HPPK (EcHPPK) for Mg-GTP is 260-fold less
than for Mg-ATP [25]. Remarkably, only two specific pterin-site
inhibitors have been reported in the literature [26]. Both are based
on the pterin substrate (Fig. 1), one featuring gem-dimethyl
substitution at the C7 position on the pyrimidine ring, the other a
phenethyl substituent at the same position. Bisubstrate analogues of
the former have been reported that display sub-micromolar affinity,
which demonstrates the feasibility of developing new inhibitors
based on bisubstrate-linking strategies [27].
S. aureus HPPK (SaHPPK) shares 34–39% sequence homology
with HPPK enzymes from other species whose structures have been
determined (Fig. 2C). High conservation of active site residues, and
high structural similarity among all HPPK structures, suggests that
HPPK inhibitors developed for one species may have advantageous
cross-reactivity over many different species.
Herein, we report the first structural studies of HPPK from S.
aureus using a combination of solution NMR and x-ray
crystallographic structure determination, and the identification of
a novel pterin-site inhibitor 8-mercaptoguanine (Fig. 2D) by in silico
ROCS screening (Rapid Overlay of Chemical Structures) and
differential scanning fluorimetry (DSF) assay. The atomic structure
of SaHPPK has been determined in complex with a new pterin-
site inhibitor, revealing the molecular details of inhibitor
association. Binding of the inhibitor, substrate and cofactor
molecules were quantified using isothermal titration calorimetry
(ITC) and surface plasmon resonance (SPR), while in vitro enzyme
inhibition data was measured using a luciferase based luminescent
assay. Detailed studies of ligand interactions using NMR highlight
critical ligand-induced dynamic changes upon inhibitor, substrate
and cofactor binding, which correlate with large entropic penalties
to the binding thermodynamics of the inhibitor measured by ITC.
Results
Enzyme stability
Buffer conditions were screened to overcome initial solubility
problems with SaHPPK using a differential scanning fluorimetry
(DSF) assay [28] and button tests [29]. Final optimized buffer
conditions from both techniques correlated well, with SaHPPK
found to be most stable in a buffer comprised of 50 mM HEPES
(pH 8.0), 1% sorbitol and 2.0–5 mM DTT.
Validation of ROCS virtual screening hits using the DSF
assay
To identify potential new binders of SaHPPK, we adopted a
high-throughput virtual screening approach (see methods) using
ROCS (Rapid Overlay of Chemical Structures) [30]. The DSF
assay used for buffer stability screening was subsequently
employed as an efficient method to screen the 37 purchased
ROCS compound library. DSF is a rapid, convenient and
inexpensive assay to detect binding of ligands to proteins. It
compares the change in the unfolding transition temperature
(DTm) of a protein obtained in the presence and absence of a ligand
[31,32]. A ligand that binds to the protein generally causes an
increase in the protein thermal melting temperature (Tm).
We tested the utility of the assay using ATP (and AMPCPP)
binding. ATP and AMPCPP bind relatively tightly to EcHPPK,
with dissociation constants of 2.6 and 0.45 mM, respectively [24].
The unfolding temperature (Tm) of SaHPPK increased by 6 and
11uC in the presence of saturating ATP and saturating AMPCPP,
respectively, which is consistent with the previously observed
tighter binding of AMPCPP to EcHPPK, as well as the results of
our ITC and SPR experiments (vide infra). Inspired by these
Figure 1. Pyrophosphoryl transfer catalysed by HPPK.
doi:10.1371/journal.pone.0029444.g001
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encouraging results, this rapid assay was used to screen the ROCS-
generated library, using a single ligand concentration of 500 mM
in 5 mM enzyme. Out of the 37 compounds tested, one
compound, 8-mercaptoguanine, produced an increase in Tm of
3.4uC (as compared to apo), confirming binding to SaHPPK
(Fig. 3A). Moreover, a similar increase in Tm was observed in the
presence or absence of ATP/AMPCPP, suggesting non-compet-
itive binding with the cofactor.
Biochemical assay
A KinaseGloTM assay was performed to test SaHPPK function
and examine whether 8-mercaptoguanine inhibits SaHPPK catalysis.
While a Km
app value of 10.862.5 mM was readily obtained for ATP,
the assay is insufficiently sensitive to allow reliable determination of
the relatively low Km for HMDP, consistent with those determined
for the E. coli enzyme (0.7–1.6 mM) using different assays [23,33]. The
assay is however suitable to show inhibition and gave an apparent
IC50 of 4169 mM for 8-mercaptoguanine (Fig. 3B).
Thermodynamics of ligand binding by ITC
To determine the affinity and thermodynamic parameters of
ligand binding to SaHPPK, we employed isothermal titration
calorimetry (ITC) (Table 1; Fig. 4). Previous studies using
fluorescence-based methods have reported a binding affinity (Kd)
Figure 3. DSF and enzyme assays. A, Superposition of the DSF assay profiles of 37 ROCS compounds (left) showing the curve for 8-
mercaptoguanine (8MG) (black) and thermal shift DT, double headed arrow) relative to the apo enzyme (blue) or relative to the AMPCPP complex
(right). The DSF assay for AMPCPP is also shown (red). B, Dose response curves for the inhibition of SaHPPK by 8-mercaptoguanine (IC50 = 41 mM).
HMDP and ATP concentrations were fixed at 0.3 mM and 0.2 mM respectively.
doi:10.1371/journal.pone.0029444.g003
Figure 2. Folate pathway, HPPK structures and HPPK sequences. A, Schematic showing the folate pathway conversion of dihydroneopterin
(DHNPt) into tetrahydrofolate (THF) via the five essential enzymes, DHNA, HPPK, DHPS, DHFS and DHFR. B, Superposition of selected HPPK structures
in complex with HMDP (orange), 8-mercaptoguanine (elemental colouring) and AMPCPP (cyan), showing the prototypical HPPK fold, active site loops,
Gly90 (red), the HPPK conserved ring stacking residues and magnesium ions (orange) bound by the conserved aspartate residues. SaHPPK (3QBC)
from this study is shown (yellow). Three EcHPPK structures are shown in complex with AMPCPP and HMDP (1Q0N, green); apo (1HKA, blue); with
HMDPP and AMP (1RAO, magenta) and HPPK from H. Influenza (1CBK, grey). C, Multiple sequence alignment of selected HPPKs. Absolutely conserved
residues (orange), highly conserved residues (blue), and residues that are additionally important for HPPK function and may be targeted to develop
selective inhibitors are shown (green). Residues involved in HMDP (*) and ATP recognition (#) and elements of secondary structure are displayed
above the alignment. Underlined sequences have had their structure determined by x-ray crystallography. D, Structure of the SaHPPK inhibitor 8-
mercaptoguanine.
doi:10.1371/journal.pone.0029444.g002
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of EcHPPK for ATP of 2.6–4.5 mM, and for AMPCPP of 0.08–
0.45 mM in the presence of Mg2+ [23,24,25]. Binding affinities of
EcHPPK for HMDP substrate vary from 0.036 to 0.17 mM in the
presence of Mg2+ and AMPCPP [23,24].
ATP and AMPCPP were shown to bind exothermically to
SaHPPK with affinities of 31 and 3.1 mM, respectively at 298 K
(Table 1; Fig. S1A). In the absence of Mg2+, no significant binding
was observed for either compound (data not shown). These
affinities are lower than those reported for EcHPPK, but we
observe a very similar affinity ratio for the two compounds, with
AMPCPP displaying approximately 10-fold tighter binding than
ATP. The inhibitor was found to bind SaHPPK with a Kd of
12.863.4 mM (Fig. 4A), with AMPCPP having no effect on the
affinity or thermodynamics of interaction. The interaction occurs
with a large favourable binding enthalpy but with a significant
entropic cost (see thermodynamic parameters in Table 1).
In saturating AMPCPP, the substrate (HMDP) bound with a Kd
of 4.061.2 mM (Fig. 4B), which is again significantly weaker than
that determined for EcHPPK by fluorescence methods [23,24]. In
the presence of the inhibitor 8-mercaptoguanine, however, binding
was reduced to a level that could not be detected by ITC. Therefore,
it appears that the inhibitor binds competitively to the same binding
site as the substrate, affecting enzyme inhibition accordingly. In line
with previous studies, we observed that HMDP binding is highly
dependent upon the prior incorporation of ATP, or the analogue
AMPCPP. Although a weak binding signal is observed for HMDP
without AMPCPP, a satisfactory fit to the data could not be
obtained, which is consistent with the low affinity estimated from
SPR experiments (see below).
Kinetics of ligand binding by SPR
Binding interactions of SaHPPK substrates, AMPCPP and 8-
mercaptoguanine were analysed via surface plasmon resonance
(SPR) using minimally biotinylated SaHPPK immobilized onto a
NeutrAvidin chip surface (Table 1, Fig. 4 and Fig. S1). In this
manner, we were able to obtain highly active SaHPPK surfaces
not compromised by a low pH required for amine coupling
method [34]. Kd values for ATP and AMPCPP were determined
to be 4562 and 7.760.4 mM, respectively, in close agreement
with the values determined by ITC (Table 1, Fig. S1A). The slower
dissociation of AMPCPP also allowed the binding affinity to be
derived by fitting to a kinetic interaction model, yielding rate and
affinity parameters of ka = 8.861.3610
4 M21 s21, kd = 0.56
0.1 s21 and a similar Kd = 5.460.3 mM (Fig. S1 A). Based on this
result, we conclude that the higher affinity of AMPCPP compared
to ATP is mainly driven by a slower dissociation rate parameter
(kd) for AMPCPP. Weak binding of ADP and AMP (Table 1, Fig.
S1B), beyond the detection limit of ITC, could be estimated by
steady-state fitting in SPR, extending the upper limit of detection.
Binding of HMDP to SaHPPK in the absence of the cofactor was
not readily detectable by ITC under the conditions used here, but
could be approximated by SPR (Kd,100 mM). The binding
affinity for the SaHPPK/HMDP interaction measured by SPR in
the presence of AMPCPP (Kd = 3.660.3 mM) was in excellent
agreement with the value obtained by ITC (Kd = 4.061.2 mM)
(Table 1, Fig. 4B). Furthermore, SPR measurements confirmed
that binding of 8-mercaptoguanine to SaHPPK was independent
of cofactor, as estimated affinity values in the presence and
absence of ATP were approximately the same (10.860.4 uM and
8.161.6 uM, respectively) (Table 1, Fig. 4A).
Backbone assignments of SaHPPK with substrate and
cofactor
The chemical shift of a nucleus is sensitive to changes in its local
environment and is thus a convenient probe for analysing ligand
binding events and detecting conformational changes. To
investigate the structure and substrate binding properties of the
enzyme, we thus assigned the backbone resonances of SaHPPK
under various ligand conditions using heteronuclear NMR
spectroscopy and compared the change in the weighted average
resultant 15N and 1HN chemical shift vector (chemical shift
perturbations, CSPs). All 15N HSQC spectra e.g. Fig. S2, showed
well-dispersed sets of resonances, consistent with a folded enzyme.
No change over time was observed in the 15N HSQC spectra of
the SaHPPK/HMDP/AMPCPP complex under the sample
conditions (see methods), at least for a period up to ,36–48 hrs
Table 1. Thermodynamic and kinetic parameters for the binding of ligands to SaHPPK, as determined by ITCa and SPRa.
Ligand
DH
(kCal mol21)
TDS
(kCal mol21)
DG
(kCal mol21) N
Kd
(mM) ITC
Kd
(mM) SPR
ATP 26.560.4 20.360.5 26.260.1 0.9860.11 31.064.5 4562
ADP ndc ndc ndc ndc ndc 760616
AMP ndc ndc ndc ndc ndc 490061100
AMPCPP 26.361.0 1.361.0 27.560.2 1.0660.12 3.161.2 7.760.4
HMDP ndc ndc ndc ndc ndc 100612
HMDP+AMPCPPb 210.561.0 23.160.9 27.460.2 1.2360.15 4.061.2 3.660.3
8MGe 219.663.4 212.963.5 26.760.2 1.0060.06 12.863.4 10.860.4
8MGe
+AMPCPPb
217.261.4 210.461.5 26.860.1 0.9660.09 11.362.3 nd
8MGe
+ATPd
nd ndc ndc ndc ndc 8.161.6
aValues are the means 6 the standard deviation for at least three experiments. See Materials and Methods for sample concentrations used. All ITC and SPR experiments
were performed at 298 K and 293 K respectively.
bConcentration of AMPCPP was 1 mM in both HPPK (cell) and ligand (syringe) solutions.
cNo data.
dConcentration of ATP was 5 mM.
e8-mercaptoguanine.
doi:10.1371/journal.pone.0029444.t001
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Figure 4. Binding of ligands to SaHPPK as measured by ITC and SPR. A, Raw (top left) and integrated ITC data (bottom left) for the titration of
30 mM SaHPPK with 300 mM 8-mercaptoguanine (8MG) alone (&), and 300 mM 8-mercaptoguanine in the presence of 1 mM AMPCPP (N). SPR raw
data (middle and right top) and steady-state response curve (middle and right bottom) for the binding of 8-mercaptoguanine in the absence (middle)
and presence (right) of 5 mM ATP. B, Raw ITC data (top left) and integrated normalised data (bottom left) for titrations of 22 mM SaHPPK with 500 mM
Structure of HPPK from S. aureus
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(Fig. S3), which was long enough to record 3D experiments to make
assignments and record relaxation experiments. Oxidation of
HMDP has been reported in previous x-ray studies [22], however,
while some degradation was observed in the 1D 1H of isolated
HMDP alone over time (data not show), spectral evidence for a
bound hydroxymethylpterin oxidation product or degradation
species were not observed (Fig. S4). It appears that degradation
over time leads to a weakly bound product which is not competitive
to the tight binding substrate. Therefore, for the first time we report
NMR data on the binding and dynamics of the substrate to HPPK.
Under physiological conditions, the SaHPPK enzyme is
expected to be saturated with ATP, given the binding constant
of ,45 mM (Table 1, Fig. S1A). Titration of SaHPPK with ATP or
AMPCPP revealed slow exchange on the NMR timescale.
Substantial CSPs were observed for both cases and large
perturbations were localized to the ATP site (Fig. S2). A titration
of SaHPPK with fresh HMDP to saturation levels showed
extensive chemical shift broadening (or disappearance) compared
to the apo 15N HSQC spectrum, and few residual CSPs. The
broadening mapped to residues within loop L2 (Fig. S2B, C) and
residues around the pterin subsite, including those of the b-sheet,
underneath the substrate. Adding HMDP to the saturated
AMPCPP complex, on the other hand, revealed slow exchange,
characteristic of tighter binding. Perturbations clearly mapped to
the pterin site, as expected (Fig. S2B, C) yet a few resonances in
loop L2 still remained broadened.
Given that the inhibitor has no non-exchangeable 1H NMR
signals and standard NMR techniques would only poorly
characterise the intermolecular interactions, we adopted a parallel
investigation of the x-ray structure in complex with 8-mercapto-
guanine.
X-ray crystallographic structure of SaHPPK in complex
with 8-mercaptoguanine at 1.65 A˚ resolution
The x-ray crystal structure of SaHPPK in complex with the
inhibitor, 8-mercaptoguanine was solved at high resolution (Fig. 5).
Crystallisation conditions were as published [35]. Briefly, the
SaHPPK/8-mercaptoguanine binary complex crystallised in the
P21 space group, with the asymmetric unit comprising two protein
molecules that contain a single bound 8-mercaptoguanine molecule
per monomer and a total of 256 water molecules (Fig. 5A). Density
was observed for all 158 amino acid residues of the protein, although
the density for residues 85–91 was very weak in monomer B. Two (in
chain A) or three (in chain B) additional non-native residues are seen
as a result of the N-terminal thrombin cleavage site.
SaHPPK has a ferredoxin-like fold (aba), with a central core of
six b strands surrounded by four helices, typical of other
monofunctional HPPK structures. The two monomers in the
asymmetric unit are almost identical, with an RMSD of 0.34 A˚ over
all 158 pairs of backbone Ca atoms. The catalytic loops L1, L2 and
L3 (residues 12–14, 47–51, 82–94) have higher than average
temperature factors, showing that they are likely mobile in solution,
which parallels the observed broadening of residues in solution by
NMR. The dimer interface encapsulates the active sites, leading to a
buried surface area of 1595 A˚, not including the inhibitor
molecules. Eight inter-subunit hydrogen bonds are observed.
Using the SSM algorithm in Coot [36], we calculated 36%
sequence identity between the structures of SaHPPK and
EcHPPK (1RAO), with a RMSD of 1.45 A˚ over the 148 aligned
residues. While the structure of SaHPPK deviates significantly
from the EcHPPK in the region leading out to the C terminus
(residues 150–156) (Fig. 2B), secondary structural elements are
generally very well conserved as they are across all HPPK enzymes
(Fig. 2B), with major variations occurring mostly in the catalytic
loops, dependant on the types of bound ligands or catalytic stage.
Comparison of 8-mercaptoguanine and HMDP binding
The crystal structure confirms that 8-mercaptoguanine binds to
the pterin pocket in a similar pose to the HMDP substrate bound in
EcHPPK (1Q0N) (Fig. 5B, C). Mercaptoguanine and HMDP share
the same pyrimidine ring, which in both cases makes hydrogen
bond contacts with several highly conserved residues; T43, A44,
V46, and N56 saturate the hydrogen bond donor/acceptor sites
(positions 1, 2, 3, 4, and 9) of the inhibitor (Fig. 5C). Like HMDP,
the pyrimidine ring of 8-mercaptoguanine is stacked between the
conserved aromatic residues, Phe54 and Phe123. A small cavity is
found near the N7 position of 8-mercaptoguanine, in which a single
water molecule resides, forming hydrogen bonds with the sidechain
of Asp95 and the N7 of 8-mercaptoguanine. Notably, two of the
interactions formed between HMDP and HPPK are absent in the
case of 8-mercaptoguanine. Firstly, the imidazole ring of 8-
mercaptoguanine is too far away to interact with Asp95, which
forms a hydrogen bond with the hydroxymethyl group of HMDP.
Secondly, a van der Waals interaction with Trp89 is missing. Loop
L3 is displaced out of the active site and the Trp89-8-mercapto-
guanine distance is around 25 A˚, compared to ,4 A˚ in the
HMDP/AMPCPP-bound structure of EcHPPK (pdb 1Q0N).
Comparison of loop positions
The three loops of HPPK (L1–L3) are highly dynamic in nature,
changing conformation during the enzymatic cycle (Fig. 2B) [37].
Loops L1 and L2 undergo relatively minor structural changes
compared to loop L3, for which the apex moves over 20 A˚ throughout
the cycle (Fig. 2B). Loop L2 in SaHPPK caps the substrate active site
and resembles closely the loops in the HMDP/AMPCPP (1Q0N) and
pterin analogue-bound forms (1DY3, 1CBK). Loop L3 in SaHPPK is
‘‘extended’’ out from the active site and, as such, resembles most
closely the loop position in the product-bound EcHPPK structure
(1RAO). It is excluded from the active site by the 108–111 loop from
the other monomer in the asymmetric unit (Fig. 5C, D).
Although we grew crystals routinely in the presence of 2 mM
AMPCPP and 10 mM Mg2+, we did not observe density for either,
even when the concentrations of these species were increased to 25
and 50 mM, respectively. We therefore performed NMR
measurements on the ternary SaHPPK/8-mercaptoguanine/
AMPCPP complex.
Chemical shift mapping of inhibitor complexes by NMR
spectroscopy
Titration of 8-mercaptoguanine into a sample of the apo enzyme
produced a range of CSPs (Fig. 6A) and exchange regimes in the
NMR spectra. 15 cross peaks broadened completely around the
binding site and along the sheet (Fig. S2D) and most others
exhibited slow exchange, indicative of a Kd likely in the low mM
range. In contrast, when performed in the presence of saturating
ATP or AMPCPP, widespread perturbations were observed in
HMDP (m) in the absence of 8-mercaptoguanine and in the presence of 300 mM 8-mercaptoguanine (N), and in the presence of 1 mM AMPCPP (&).
Binding of HMDP was only detected in the presence of AMPCPP. SPR raw data (middle and right top) and steady-state response curve (middle and
right bottom) for the binding of HMDP in the absence or presence of saturated AMPCPP.
doi:10.1371/journal.pone.0029444.g004
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slow exchange for all resonances, despite no change in binding
affinity measured by ITC and SPR. Chemical shift perturbations
clearly mapped to the respective substrate and cofactor site (Fig.
S2D).
All 15N and 1HN amide chemical shifts are tabulated in Table.
S1 and values for CSPs are shown in Fig. S5.
SaHPPK is a monomer in solution
The 15N T1/T2 ratio for amides of SaHPPK in the presence of
8-mercaptoguanine and AMPCPP correlated well with that
calculated using HYDRONMR [38] for a monomeric enzyme
with a correlation time of ,12 ns (Fig. S6). This clearly showed
that the enzyme exists as a monomer in solution at a concentration
less than ,200 mM. Line widths were similar for the SaHPPK/8-
mercaptoguanine binary complex.
The linewidth and chemical shift of Gly90 amide
indicates a loop ordering in the vicinity of the inhibitorfor
the inhibited ternary complex
We observed that the amide of Gly90 displayed a large upfield
CSP, and sharpened significantly, when comparing the spectrum of
the SaHPPK/AMPCPP complex to that of the SaHPPK/8-
mercaptoguanine/AMPCPP complex (Fig. 6C). In addition, a similar
but smaller shift was observed in the SaHPPK/HMDP/AMPCPP
Figure 5. X-ray structure of SaHPPK with the 8-mercaptoguanine inhibitor bound. A Ribbon schematic showing the crystallographic dimer of
theSaHPPK-8-mercaptoguanine binary complex. B, F0-Fc difference density map of 8-mercaptoguanine contoured at 3.0 sigma. C, Intermolecular
interactions (orange) involving 8-mercaptoguanine. Two side chain conformers for Asp95 were modelled and are shown. The second monomer is drawn in
yellow ribbon. The oxygen atom of a water molecule forming hydrogen-bonds with 8-mercaptoguanine and SaHPPK is shown in green. D, Space filling
representation of the dimer interface, showing 8-mercaptoguanine bound in the deep pterin pocket, sandwiched between Phe123 and Phe54 (purple), and
illustrating the proximity to the 110 s loop in the other monomer. E, Final 2F0-Fc electron density map of the pterin binding site, contoured at 2.0 sigma.
doi:10.1371/journal.pone.0029444.g005
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complex and Gly90 was noticeably broadened (Fig. 6C). Such CSP
reflects a dramatic change in the environment and a decrease in local
chemical exchange effects respectively, likely associated with a
decrease in the motion of loop L3 on the ms-ms timescale. Further
evidence for a decrease in loop L3 dynamics is supported by more
extensive assignments in loop L3 for the SaHPPK/8-mercaptogua-
nine/AMPCPP spectra relative to all other spectra (compare the
ribbon diagrams in Fig. S2B with Fig. S2D).
15N fast timescale dynamics uncovers distinct loop
dampening in the inhibited ternary complex
To understand the fast timescale motion of SaHPPK in solution
we recorded 15N heteronuclear NOE data for the apo enzyme, the
binary SaHPPK/ATP complex and the SaHPPK/8-mercapto-
guanine/AMPCPP ternary complexes (Fig. 6D). Data for the 8-
mercaptoguanine or HMDP binary complexes were not recorded
owing to extensive broadening around the substrate site.
In all cases, the last and first residues showed relatively low 15N
NOE values (,0.4–0.6) and are therefore partially mobile on the ps-
ns timescale. The amides of Val46–Gln51 in loop L2 were also
mobile for the ATP-bound and apo samples. Gly90 was found to be
mobile on fast timescale in apo and ATP-bound SaHPPK. Val124,
the residue adjacent in sequence to the ring-stacking Phe123,
appeared to be mobile on the ps–ns timescale (NOE,0.6) with all
substrates.While Lys110 is mobile in the apo enzyme signal overlap
precluded assessment of this residue in the complexes.
For the ternary SaHPPK/8-mercaptoguanine/AMPCPP com-
plex, apart from Tyr48, the fast motions within loop L2 diminish
and the loop essentially becomes rigid around the inhibitor (Fig. 6D).
This is in contrast to the SaHPPK/HMDP/AMPCPP complex
which remains partially mobile. While the fast motions of Gly90 and
the sidechain He1 of Trp89 are considerably dampened in the
inhibited ternary complex compared to all other complexes, there is
evidence for slower underlying motion particularly in the 84–88
region as judged by resonance broadening. Finally, the fast
timescale motion that was evident in Val124 (15N NOE,0.5) in
all other spectra also appears to dampen and this amide becomes
rigid in the SaHPPK/8-mercaptoguanine/AMPCPP complex.
15N Residual dipolar couplings (RDCs) support a closed
loop L3 conformation for the inhibited ternary complex
in solution
To understand the structure of the inhibited ternary complex in
solution we recorded 1DHN residual dipolar couplings (RDCs) of
each amide. These are induced by the weak alignment of a
biomolecule in solution and report the angle a given N-H vector
makes within the principal axis system of the alignment tensor.
Weak alignment of SaHPPK was achieved with a PEG/hexanol
alignment media [39] from which RDCs up to ,20 Hz in
magnitude were measured (see methods). These allowed us to
derive the alignment tensor by single value decomposition within
PALES [40] by fitting the measured 1DHN
15N RDCs to our x-ray
structure (Fig. 6E). The striking agreement (Pearson’s correlation
coefficient (R2) = 0.97, Q factor = 24%) between the ternary
SaHPPK/8-mercaptoguanine/AMPCPP complex in solution with
the binary SaHPPK/8-mercaptoguanine x-ray structure shows
that, overall the binary structure is a very good model for the
ternary structure in solution. Similarly oriented amides within
helix 1 for example (residues 14–28) lie parallel to the principal
axis of the alignment tensor as evidenced by a string of fairly
uniform RDCs with maximal value. Helix 2 on the other hand
shows smaller RDCs and larger sinusoidal fluctuations as it is tilted
away from the principal axis.
A few RDCs stand out as outliers. Interestingly, these generally
map to those amides in close proximity to a ligand or metal.
Residues 123–125 showed very small RDCs (0.38, 1.0, and
21.42 Hz respectively) and their calculated values (28.7, 23.8,
4.8 Hz) result in statistically significant deviations (.,5 Hz). Low
values of the RDC can result from motional averaging of the
amide vector or if the NH vector points close to the magic angle
with respect to the Z axis of the alignment tensor. As the 15N NOE
values are high for residues 123–125, the RDC data suggest small
tilts of these amide vectors in solution towards the magic angle
compared to those of the x-ray structure. Calculations show that
rotations of 18, 36 and 22u giving small displacements of 0.3, 0.6
and 0.4 A˚ respectively in the amide proton coordinate can
accommodate these observed RDC values.
The 1DHN RDC for Tyr48 (2.7 Hz) deviates from the
calculated (14.2 Hz) and given the 15N NOE,0.55 is most
likely due to motion. The measured RDC for Asp95 (210.9 Hz)
deviated markedly from that calculated from the SaHPPK/8-
mercaptoguanine x-ray structure (23.3 Hz), but agreed very well
to the amide orientation calculated (212.3 Hz) for the
EcHPPK/HMDP/AMPCPP ternary structure (1Q0N) indicat-
ing that a ,30u reorientation of its H-N vectoris likely in the
SaHPPK/AMPCPP/8-mercaptoguanine ternary complex. In-
terestingly, for the Gly90 amide in loop L3, the agreement with
our x-ray structure is very poor indeed and of opposite sign,
deviating by over 9 Hz. However, there is a close agreement
(1.5 Hz) with the EcHPPK/HMDP/AMPCPP (1Q0N) orienta-
tion (Fig. 6E).
Discussion
This work reports the discovery, binding properties and
mechanism of a novel, competitive pterin site inhibitor, presented
in complex with the first crystal structure of SaHPPK. The pterin
site is highly specific and restricts the chemical space available for
inhibitor design to structures closely resembling the pterin scaffold.
Consequently, the literature is devoid of non-pterin like HPPK
inhibitors [41], despite mounting structural information that has
been reported over the last decade. In line with the high pterin-site
specificity is the high ligand efficiency (2.3 kJ/heavy atom
orKd,13 mM over 12 heavy atoms) of 8-mercaptoguanine.
8-Mercaptoguanine has previously been reported to have
biological activity. Early studies revealed some lipolytic activity
[42] while in a number of cases 8-mercaptoguanine has been
Figure 6. Binding of 8-mercaptoguanine (8 MG) to SaHPPK by NMR spectroscopy reveals an ‘in’ conformation of loop L3. A,
Superposition of the 15N HSQC spectra of ,100 mM SaHPPK with and without 0.6 mM 8-mercaptoguanine (left), and the 15N HSQC spectra of
,100 mM SaHPPK+1 mM AMPCPP+10 mM Mg2+ with and without the addition of 600 mM 8-mercaptoguanine. B, Superposition of the EcHPPK/
AMPCPP/HMDP (1Q0N, grey ribbon, blue sidechain, green ligands) with SaHPPK (yellow). The loop L3 ‘in’ conformation and the loop ‘out’
conformation are shown for each respectively and the sidechain of Trp89 and Pro91. C, Region of the superposed 15N HSQC spectra of apoSaHPPK
(red), SaHPPK/ATP complex (blue), SaHPPK/HMDP/AMPCPP complex (green) and SaHPPK/8-mercaptoguanine/AMPCPP complex (black). The large
CSP of G90 is shown. D, Superposition of the 15N heteronuclear NOE values recorded at 600 MHz. The colour coding is the same as in C). Open circles
are for the He1 of Trp89. The extent of the secondary structural elements is shown at the top, with the region corresponding to the active site loops,
L2 and L3, highlighted. E, Comparison of observed (black) and calculated (red) 1DHN RDCs for SaHPPK/8-mercaptoguanine/AMPCPP. The
1DHN RDC for
G90 from EcHPPK/HMDP/AMPCPP (1Q0N) is shown (green filled circle).
doi:10.1371/journal.pone.0029444.g006
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shown to inhibit enzymes that normally bind purines
[43,44,45,46]. Antiviral activity,without significant toxicity, was
also reported in an in vivo mouse model [43]. Close analogues, such
as 8-mercaptoguanosine, were also shown to induce interleukin-1
activity in macrophages [47]. Despite these studies, no antibac-
terial activity has been reported previously. Interestingly, 8-
mercaptoguanine has been shown to bind to, but not inhibit, B.
anthracis DHPS by co-crystallisation [48], which may open the
possibility for a multi target inhibitor derived from this scaffold. In
the present work, we did not observe growth inhibition in vivo by 8-
mercaptoguanine in E. coli cell-based assays (data not shown).
Given the unfavourable logP (20.39), this is likely to be due to
poor membrane permeability. This may be a disadvantage for
pterin-like inhibitors in general given the hydrophilic nature and
restrictive chemical space of the pterin scaffold in folate pathway
enzymes. Nevertheless, while insufficient transport of a set of
closely related pyrimidines as potential antifolates was implicated
in their poor in vivo inhibition, derivatives with an additional
phenyl substituent displayed sub micromolar activity in vivo to T.
brucei and L. major [49]. The known phenethyl in vitro inhibitor of
HPPK (pdb 1DY3) suggests that a suitably positioned phenyl
group on 8-mercaptoguanine may thus be beneficial to both
binding and assist cell permeability.
Given that 8-mercaptoguanine forms exactly the same number
of inter-molecular hydrogen bonds as the substrate heterocyclic
rings, an intriguing finding from our work is that, in the absence of
cofactor, the inhibitor binds some 10-times more tightly
(Kd,12 mM) than HMDP (Kd,100 mM by SPR). In the
HMDP/AMPCPP complex the higher affinity (Kd,4 mM) of
substrate can be rationalised by the observation of a hydrogen
bond to the Mg2+ bound c-phosphate of AMPCPP from the
HMDP hydroxyl as seen in the EcHPPK/HMDP/AMPCPP
(1Q0N) ternary complex [21,41]. We therefore hypothesised that
the large increase in the DG of binding might be associated directly
with the sulfur atom in 8-mercaptoguanine, in the absence of
substantial de-solvation or structural differences. While our
SaHPPK structure is a valuable resource and will support further
inhibitor design strategies towards the phosphate sub-site, the ‘out’
position of loop L3 in our crystallographic dimer precluded us
from drawing many conclusions about the nature of the
interaction between the sulfur atom of the inhibitor and enzyme.
Nevertheless, we have established from several different types of
NMR data that residue Gly90 is in close contact with the sulfur
atom of the inhibitor in solution (Fig. 6).
In the EcHPPK/HMDP/AMPCPP ternary complex (1Q0N), the
tip of loop L3 is observed closed ‘in’ over the active site with the
Trp89 sidechain He1 hydrogen bonded to the terminal phosphate. A
superposition of this ternary complex with our crystal structure
indicates that the sulfur atom of the inhibitor would lie ,4.6 A˚ from
the sidechain of Trp89 and only ,3.9 A˚ from the N atom of Gly90
(Fig. 6B). The importance of this proximity is likely to account for a
specific interaction to the inhibitor and thereby stabilizing loop L3
into the ‘in’ position. For this loop arrangement and in a protonated
thiol tautomer of the inhibitor, a hydrogen bond is predicted between
the thiol proton and the backbone carbonyl of Gly90. The large 15N
chemical shift perturbation (,7 ppm),15N spin relaxation data and
NMR linewidth considerations (Fig. 6) is evidence that the Gly90
amide is in close proximity and, along with the sidechain of Trp89,
becomes essentially rigid in the ternary SaHPPK/inhibitor/
AMPCPP complex. A direct interaction with the inhibitor is not
possible from a solvent exposed Gly90/Trp89 in a loop L3 ‘open’
arrangement. In agreement with an important role of the sulfur atom
of 8-mercaptoguanine in HPPK binding, guanine, the sulfur-free
analogue of the inhibitor, displays markedly reduced affinity that was
undetectable by SPR (data not shown) and gave few CSPs in the
NMR spectra (data not shown). Finally, the close agreement of the
15N RDC for Gly90 to the EcHPPK ternary complex structure
(1Q0N) (Fig. 6E) is evidence that G90 amide is oriented in solution as
that in 1Q0N and thus further evidence of the loop ‘in’ conformation.
Active site motions and associated changes in loop conforma-
tions are an intrinsic requirement for enzyme activity [50] and for
the structural transitions along the catalytic pathway of HPPK
[51]. We propose that the thiol-mediated stabilization of loop L3
in turn stabilizes interactions to the neighbouring substrate loop
L2. ITC data is in agreement with 15N relaxation data and showed
a significant-binding entropy penalty for 8-mercaptoguanine
binding to the SaHPPK/AMPCPP complex supporting the
contention that the loops L2 and L3 (particularly around Gly90)
become more ordered. In contrast, the lower entropic penalty for
the binding of the substrate to SaHPPK/AMPCPP is in accord
with a partially mobile loop L2 and loop L3 which is likely to be
functionally relevant to facilitate subtle structural changes, during
pyrophosphoryl transfer. Inhibition by 8-mercaptoguanine there-
fore may be derived in part from impeding a catalytic role of loop
L3.This notion is consistent with the observation that the loop L3
deletion in EcHPPK did not affect ATP affinity, but produced a
105-fold decrease in the rate constant for catalysis [20].
Intermolecular interactions to loop regions, may compromise an
inhibitor as a potential long-term antimicrobial candidate. It is
well documented that point mutations in loop regions have
resulted in rapid sulfa drug resistance in the downstream DHPS
enzyme [12,48]. Given the C8 thiol of 8-mercaptoguanine seems
to make an important backbone, rather than sidechain interaction
with the highly conserved Gly90 or other natively small residue
substitutions (Ala or Ser) in other species, (Fig. 2), this portion of
the molecule may be a beneficial component of the pharmaco-
phore in future chemical elaboration.
Over the last decade there has been a growing interest in using RDC
calculations as a powerful additional parameter for the validation and
refinement of macromolecular structures [52,53]. Recently, chemical
shift changes in conjunction with 1DHN RDC measurements have
revealed ligand induced conformational changes in the active site loop
in ABL kinase [54]. Here, we have established unequivocally that the
SaHPPK/8-mercaptoguanine/AMPCPP ternary structure in solution
is essentially the same as the x-ray structure of the binary inhibited
complex (for all residues that we could measure 1DHN RDCs) and that
loop L3 is likely ‘in’ (Fig. 6E). Furthermore, several NOEs to the H2
and H8 of AMPCPP were observed from amides 98, 111 and 112 in
the 3D 15N NOESY HSQC experiment, consistent with the pose of
the adenine found in the EcHPPK structure (1Q0N) (data not shown).
These data show that our structure is also a good working model of the
adenine-binding pocket.
In summary, our multi-disciplinary study shows that 8-
mercaptoguanine readily binds to SaHPPK with high ligand
efficiency and dampens loop motions by making specific
interactions to both catalytic loops. It inhibits enzyme function in
vitro and thus presents as an important scaffold for development of
SaHPPK inhibitors with increased potency and more favourable
pharmacokinetic properties. Conservation of the binding site
within HPPK enzymes from E. coli, H. influenza, Y. pestis, S. cerevisiae
and F. tularensis indicates that 8-mercaptoguanine may also be
active against a range of other bacterial and lower eukaryotic
enzymes. Accordingly, 8-mercaptoguanine may present a novel
scaffold for future broad spectrum antibiotic development in the
treatment of S. aureus and other pathogenic infections. We are
currently exploring elaboration of the 8-mercaptoguanine scaffold
to this end.
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Methods
Crystallisation and x-ray structure determination
SaHPPK was expressed, purified and crystallised as described
previously [35]. The initial phases of the binary complex were
determined by molecular replacement using Phaser [55] as
reported [35]. Prior to molecular-replacement calculations, the
ligands (AMP, HMDPPP) and solvent molecules were omitted.
Refinement was performed using REFMAC5 [56] and the Fourier
maps (2Fo2Fc and Fo2Fc) were visualized in Coot [57]. After several
rounds of manual rebuilding, 8-mercaptoguanine and water
molecules were added and the model further refined to a
resolution of 1.65 A˚. Structure validation was conducted using
PROCHECK [58]. Table 2 provides the statistics for the x-ray data
collection and final refined model.
Preparation of isotopically-labelled protein for NMR
spectroscopy
Isotopically-labelled protein samples for NMR spectroscopy
were prepared as follows: E. coli BL21 (DE3) cells (Agilent)
transformed with the plasmid were grown overnight in 3 mL of
26YT media supplemented with 100 mg mL21 kanamycin for
selection. The overnight culture was subcultured into 50 mL of
minimal media that was grown to an OD600 of 0.5–0.7. This was
then added to 1 L of minimal media supplemented with 1.5 g of
15N ammonium chloride and 3 g of 13C glucose and grown at
310 K until the OD600 was 0.5–0.8. Isopropyl b-D-1-thiogalacto-
pyranoside (IPTG) was added to a final optimised concentration of
0.5 mM and expression was carried out at 293 K for 12 hr.
Purification was as reported previously [35].
Table 2. X-ray structure data processing and refinement statistics.
Spacegroup Monoclinic, P21
x-ray source MX2, Australian Synchrotron
Detector ADSC Quantum 315
Wavelength (A˚) 13000 eV (0.96A˚)
Unit-cell parameters (A˚, u) a = 36.8, b = 76.6, c = 51.5 90, a= c= 90.0, b= 100.2,
Diffraction data
Resolution range (A˚) 50.70-1.65 (1.74-1.65)
No. of unique reflections 33864 (4934)
No. of observed reflections 242194
Matthews coefficient, VM (A˚
3 Da21) 2.04
Solvent content (%) 39.6
Completeness (%) 100 (100)
Data redundancy 7.2 (7.2)
Mean I/s(I) 18.3 (4.7)
Rmerge (%)
* 10.22(0.447)
Rp.i.m. (%)
# 4.1 (17.8)
Refinement (42.3–1.65 A˚)
Rfree (%) 22.5
Rcryst (%) 17.9
Size of Rfree set (%) 5
Protein native residues (dimer) 316
8-MERCAPTOGUANINE Molecules 2
Water molecules 254
RMSD from ideal values:
Bond lengths (A˚) 0.024
Bond angles (u) 2.16
Mean B factors (A˚2) 14.7
Ramachandran plot
Residues in most favored regions (%) 91.6
Residues in additionally allowed regions (%) 8.1
Residues in generously allowed regions (%) 0.4
Residues in disallowed regions (%) 0.0
*Rmerge =ShSi |Ii(h)2,I(h).|/ShSiIi (h),
#Rpim =Sh [1/(N-1)]1/2 Si |Ii(h)2,I(h).|/ShSiIi (h).
Values in parentheses refer to the outer resolution shell (1.74-1.65A˚).
Where I is the observed intensity, ,I. is the average intensity of multiple observations from symmetry-related reflections, and N is redundancy.
Rvalue = _jjFoj _ jFcjj/_jFoj, where Fo and Fc are the observed and calculated structure factors. For Rfree the sum is done on the test set reflections (5% of total reflections),
for Rwork on the remaining reflections.
doi:10.1371/journal.pone.0029444.t002
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NMR spectroscopy
All NMR experiments were recorded at 295 K on a Varian
Inova 600 MHz NMR spectrometer equipped with a cryoprobe
and Z axis gradient. Triple resonance assignments were performed
on SaHPPK, firstly in the presence of 10 mM Mg2+ and 1 mM
AMPCPP, and secondly with the further addition of 0.6 mM 8-
mercaptoguanine. 15N/13C-labelled SaHPPK was typically 0.15–
0.25 mM in NMR buffer (90%/10% H2O/D2O buffer of 50 mM
HEPES pH 8.0, 1% sorbitol, 10 mM DTT). Backbone assign-
ments were obtained on these samples using the following triple
resonance experiments: HNCO, HNCA, HN(CO)CA, HNCACB,
CBCA(CO)NH. Assignments were further confirmed using a 3D
15N-edited NOESY experiment recorded with a mixing time of
120 ms [59]. The 15N 1HN assignments of the following samples
were derived from a pair of 3D experiments; a 15N edited NOESY
experiment recorded with a mixing time of 120 ms and a HNCA
experiment: apoSaHPPK, SaHPPK in the presence of 0.6 mM 8-
mercaptoguanine, and SaHPPK in the presence of 1 mM
HMDP/10 mM Mg2+/1 mM AMPCPP in NMR buffer. Titra-
tions were performed by titrating ligands into 0.1 mM15N-labelled
SaHPPK protein samples and recording a soFast15N HMQC
spectrum [60].
HMDP is prone to oxidation and degradation [22] which has
complicated x-ray or NMR studies to date. No change was
observed in the protein spectra over the time-course of all NMR
experiments (,48 hrs, Fig. S3). Samples were routinely sealed
under nitrogen for all lengthy NMR experiments to slow disulfide
mediated aggregation or air/light induced degradation of HMDP.
15N relaxation data were recorded on ,0.15 mM 15N-labelled
samples of SaHPPK. 15N heteronuclear NOE spectra were
recorded using TROSY-type selection and with watergate
suppression [61], owing to superior sensitivity compared to the
sensitivity-enhanced version [62] on the Varian cryoprobe. Three
seconds of weak presaturation was used to generate the desired
heteronuclear NOE, and was applied on- or off-resonance at the
amide proton frequency, in addition to 1 s of relaxation delay. T1
and T2 relaxation data were acquired as described [62]. The
relaxation delay was sampled at 10, 30, 60, 90, 110, 200, 500,
600 ms, and 10, 30, 50, 70, 90, 110 ms for longitudinal and
transverse relaxation measurements, respectively. Spectra were
processed using nmrPipe [63] and analysed with XEASY [64] or
SPARKY [65].Titration and relaxation 2D experiments were
acquired with t1max (
15N) = 51–62 ms and t2max(
1H) = 142 ms.
1DNH RDCs were measured on a ,0.1 mM 15N-labelled
SaHPPK sample in the presence of an anisotropic media
comprising 5% (wt/vol) C12E6/hexanol [39]. RDCs were
obtained by comparing coupled spectra in the presence of the
orienting media against spectra in the isotropic state by recording
a 2D 15N IPAP-HSQC spectrum [66]. RDCs were measured
using SPARKY as the isotropic (J) – aligned (J+1DNH) values
recorded in the 15N (t1) dimension. 114 1DNH RDCs were fitted to
the x-ray structure using single value decomposition incorporated
into the ‘‘bestFit’’ module within PALES [40]. The 1DNH RDCs
were removed for couplings derived from severely overlapping
peaks in the 2D IPAP spectra and mobile residues as inferred from
15N relaxation data. The error in the RDC was conservatively
estimated as +/2 1 Hz, according to the ratio of the linewidth to
the signal-to-noise. Final values of Da and Rhombicity were
9.6 Hz and 0.53 respectively.
Virtual screening using ROCS (Rapid Overlay of Chemical
Structures)
An in-silico database comprised of 229,172 commercially
purchasable compounds (Maybridge, Chembridge and Specs
libraries) was used for the screening. Database compounds were
first converted from 2D sdf format into 3D coordinates using
LigPrep within Maestro [67]. A ROCS [68] run was then initiated
to screen the database for potential pterin site binders using
HMDP as the query molecule. The top 500 hits were ranked
according to combined volume overlap (Tversky) and chemical
functionality (Colour) scores. The hits were overlayed onto the
crystal structure of EcHPPK bound to HMDP (1Q0N). Filtering of
incompatible molecules was first assessed by manual inspection of
the hits within the pterin binding pocket and compounds that
showed any possible steric clashes were discarded. ROCS hits
were chosen that retained key pharmacophore interactions in the
pterin binding site and those that provided synthetic opportunities
for scaffold optimization. A total of 44 compounds were selected
and of these, 37 were available for purchase.
Differential Scanning Fluorimetry (DSF) assay for ligand
binding
A 96-well plate containing solutions of 2–5 mM SaHPPK, 106
Sypro orange dye and 500 mM of test compound in buffer (50 mM
HEPES (pH 8.0), 1% sorbitol, 2.0 mM DTT, 10 mM MgCl2) was
heated from 298 to 322 K at a rate of 1.0 K min21. The
fluorescence intensity was measured with excitation/emission
wavelengths of 583/610 nm. Tm and DTm values were determined
from the melting curves obtained.
Isothermal calorimetry (ITC)
Experiments were performed using an iTC200 instrument
(MicroCal) at 298 K, with ligands titrated into solutions of
SaHPPK using 1862.2 mL or 1363.1 mL injections. Data were
fitted using Origin software to yield the thermodynamic
parameters, DH, Kd and N (the binding stoichiometry), assuming
a cell volume of 0.2 mL. These were then used to calculate the
Gibb’s free energy of binding, DG (2RT.lnKa), and entropy of
binding, DS (using DG=DH2TDS). For titrations with AMPCPP,
SaHPPK and AMPCPP concentrations were typically 30 and
400 mM, respectively. For titrations with ATP, SaHPPK was
typically at 70 mM and ATP at 1500 mM. For titrations with
HMDP substrate, SaHPPK was typically at 22 mM and HMDP at
500 mM, with AMPCPP added to both solutions at 1 mM where
indicated. For titrations with 8-mercaptoguanine, SaHPPK was
typically at 11 mM and inhibitor at 300 mM. Inhibitor was
prepared as a 200 mM stock solution in DMSO, and diluted into
ITC buffer to a nominal concentration of 500 mM, with an equal
0.25% DMSO added to the SaHPPK sample to ensure buffer
matching. Experiments were limited by the solubility of 8-
mercaptoguanine, estimated to be ,300 mM from ITC experi-
ments assuming a 1:1 binding stoichiometry.
Surface plasmon resonance (SPR)
Minimal biotinylation of SaHPPK was performed as follows:
SaHPPK (,30 nanomolar) in SPR ‘‘capture buffer’’ (50 mM
HEPES, pH8.0, 150 mMNaCl, 0.05% (v/v) polysorbate 20, 5 mM
DTT, 10 mM MgCl2) was incubated with an equimolar concen-
tration of EZ-LinkH Sulfo-NHS-LC-LC-Biotin (Pierce) on ice for
2 hours [69]. The biotinylated enzyme was passed through a
Superdex 75 (10/300 GL) column equilibrated with SPR capture
buffer to remove free biotin. NeutrAvidin (Pierce) was immobilized
at 298 K onto a CM5 sensor chip docked in a Biacore T100
instrument (GE Healthcare) as described previously [70], resulting
in immobilization levels of approximately 13,000 RU in all flow
cells. The biotinylated SaHPPK was bound to the NeutrAvidin chip
surface by injecting at 10 mL min21 for 6 min over a single flow cell,
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typically resulting in immobilization of,10,000 RU of SaHPPK. A
minimally-biotinylated bovine carbonic anhydrase II protein was
captured in a separate flow cell to provide an unrelated negative
control. The blank (typically flow cell 1) and captured surfaces were
subsequently blocked with three 1 min injections of 1 mg mL21 D-
biotin (Sigma) at 10 mL min21.
All SPR binding experiments were performed at 293 K in SPR
capture buffer with 5% (v/v) DMSO added. Small molecules
(ligands) were serially diluted (either 2- or 3-fold) in SPR binding
buffer and injected for 30 sec contact time at 60 mL min21, then
allowed to dissociate for 60 sec. SPR running buffer was injected
after each ligand injection to ensure complete regeneration of
immobilized SaHPPK. Each ligand titration was performed in
triplicate. Binding sensorgrams were processed, solvent-corrected
and double-referenced using Scrubber software (BioLogic Soft-
ware, Australia). Responses at equilibrium for each analyte were
fitted to a 1:1 steady-state affinity model available within Scrubber
to determine the Kd. Where the dissociation rate was sufficiently
slow, binding data were fit globally to a 1:1 kinetic interaction
model that included a mass transport component [71] and the Kd
determined from the (kd/ka) ratio.
KinaseGloTM Biochemical assay
The KinaseGloTM assay kit (Promega) was used to quantify
HPPK activity. In this assay, firefly luciferase utilizes the ATP
remaining after HPPK catalysis to produce a luminescence signal
that is directly proportional to ATP concentration; from this, the
HPPK activity can be derived. The enzyme activity and optimum
concentration to define kinetic parameters was determined by
measuring the initial rate of ATP consumption over a range of
HPPK concentrations in the presence and absence of HMDP
substrate (data not shown). For kinetic measurements, an
optimized HPPK concentration of 7 ng/50 mL assay volume
was determined, which allowed for monitoring the first 10% of
reactions turnover in a reasonable assay time period (20 min).
Measurements were performed in 96-well plates using assay
buffer (100 mMTris-HCl/10 mM MgCl2, pH 8.5, 0.01% (w/v)
BSA, 0.01% (v/v) Tween 20 and 10 mM b-mercaptoethanol).
Typically, 5 ml of test compound (dissolved in 50% DMSO) and
20 ml of enzyme were added to each well followed by 25 ml of assay
buffer giving 0.3 mM pterin and 0.2 mM ATP in a total reaction
volume 50 ml. After a 20 minute incubation at room temperature,
the enzymatic reaction was stopped with 50 ml of KinaseGloTM
reagent. Luminescence was recorded after a further 10 min using
the FLUOstar Optima plate reader (BMG, Labtech Ltd). Kinetic data
and inhibition data were fit to Michaelis-Mentenand sigmoidal
dose-response equations respectively, using GraphPad Prism.
Accession Numbers
The coordinates and structure factors of SaHPPK in complex
with 8-mercaptoguanine have been deposited in the RCSB Protein
Data Bank with accession number 3QBC.
Supporting Information
Figure S1 A) ITC (left) and SPR data (right) for binding of ATP
and AMPCPP to SaHPPK. Equilibrium binding constants (Kd) are
shown. B) SPR data for the binding of ADP and AMP to SaHPPK.
(DOCX)
Figure S2 Binding of substrate, cofactor and inhibitor
to SaHPPK as measured by NMR spectroscopy. A,
Superposition of the 15N HSQC spectra of ,100 mM
SaHPPK+10 mM MgSO4 with and without 1 mM AMPCPP
(left), and the 15N HSQC spectra of ,100 mM SaHPPK+1 mM
AMPCPP with and without 1 mM HMDP (right). B, Missing
amides are shown on a ribbon representation for apo HPPK
(green) and those that additionally disappear in the presence of
various saturating ligands (blue). C, Missing amides and CSPs
mapped onto surface of HPPK. Residues with missing resonances
in the apo enzyme are coloured cyan, whilst those additionally
broadened are coloured magenta upon binding of ligands.
Residues displaying slow exchange CSPs upon ligand binding in
the AMPCPP binary and AMPCPP+8-mercaptoguanine com-
plexes are shaded red, with the hue corresponding to the
magnitude of the CSPs. The position of the AMPCPP is modeled
from that in the E. coli HPPK (1Q0N). D, Missing amides with
addition of saturating 8-mercaptoguanine are coloured magenta.
CSPs for the slow exchange 8-mercaptoguanine+AMPCPP
ternary complex are coloured red. Missing amides are further
shown on the ribbon representation in green.
(DOCX)
Figure S3 15N sofast HMQC spectra recorded (20 min
per spectrum) over the time period shown for ,100 mM
SaHPPK in complex with either 200 mM HMDP/1 mM
AMPCPP (left) and 200 mM oxidized HMDP/1 mM
AMPCPP (right). Several spectral changes are observed in the
oxidized HMDP/AMPCPP (right) over time but not in HMDP/
AMPCPP (left).
(DOCX)
Figure S4 1H NMR spectra of 5 mM HMDP/5 mM DTT
(top) and 20 mM oxidized HMDP (bottom). Both spectra
were recorded in 50 mM Potassium phosphate buffer D2O
pH 7.9. The very small amount of oxidation of HMDP is just
visible at ,8.6 ppm in the top spectrum. The spectra show the
initial purity of the HMDP used in the NMR experiments in S3.
(DOCX)
Figure S5 CSP data for various ligands binding to
SaHPPK. From top to bottom: HMDP, AMPCPP, Pteri-
n+AMPCPP, 8-mercaptoguanine, 8-mercaptoguanine+AMPCPP.
Grey regions indicate residues for which resonances were
extensively/fully broadened compared to the apo 15N HSQC
spectrum, and therefore not observed. The CSPs were calculated
using the following equation: Dd= !(dN1560.154)2+(dHN1)2), d
refers to the chemical shift change in ppm of the resonance relative
to the apo SaHPPK 15N HSQC spectrum.
(DOCX)
Figure S6 Comparison of the HYDRONMR calculated
15N T1/T2 ratio (600 MHz) for a monomer SaHPPK
(black) and the x-ray SaHPPK dimer (red) with the
measured 15N T1/T2 (blue) for SaHPPK in complex with
8-mercaptoguanine and AMPCPP.
(DOCX)
Table S1 15N and 1HN chemical shifts (ppm) for;
SaHPPK, SaHPPK/AMPCPP, SaHPPK/HMDP, SaHP
PK/8-mercaptoguanine/AMPCPP, SaHPPK/8-mercap-
toguanine. Chemical shifts in red are from the 15Ne1 and
1He1 resonance of Trp89.
(DOCX)
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